Withangulatin A
Based on 1 publication(s) in Google Scholar
Withangulatin A is the inhibitor for COX-2. Withangulatin A inhibits MAPK, NF-κB, Akt/mTOR/p70S6K pathway, exhibits antitumor, anti-inflammatory and trypanocidal activities.
For research use only. We do not sell to patients.
- Purity: 99.76%
- CAS No.: 120824-03-5
- Formula: C30H38O8
- Molecular Weight:526.62
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Withangulatin A
MoreAll Parasite Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
2.37 μM
Compound: 1; WA
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 32886510] |
| HepG2 | IC50 |
2.85 μM
Compound: 1; WA
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 32886510] |
| HK-2 | IC50 |
6.41 μM
Compound: 1; WA
|
Cytotoxicity against human HK2 cells assessed as cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HK2 cells assessed as cell viability incubated for 24 hrs by MTT assay
|
[PMID: 32886510] |
| HT-29 | IC50 |
2.48 μM
Compound: 1; WA
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 32886510] |
| L02 | IC50 |
8.21 μM
Compound: 1; WA
|
Cytotoxicity against human L02 cells assessed as cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as cell viability incubated for 24 hrs by MTT assay
|
[PMID: 32886510] |
| MCF7 | IC50 |
6.32 μM
Compound: 1; WA
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 32886510] |
Withangulatin A (1.4-5.6 µM, 48 h) inhibits the proliferation of mouse T lymphocyte with an EC50 of 2.89 µM[1].
Withangulatin A (1.4-5.6 µM, 48 h) reduces LPS (HY-D1056)-induced secretion of IL-2, IFN-γ, and IL-6, suppresses the expression of COX-2 and PGE2 in mouse T lymphocyte[1].
Withangulatin A (0-20 µM, 24 h) arrests the cell cycle at S phase, induces apoptosis inLX-2 cell[2].
Withangulatin A (0-20 µM, 24 h) inhibits TGF-β-stimulated collagen I gene expression, inhibits the phosphorylation and nuclear translocation of Smad2/3 in rat primary hepatic stellate cells and LX-2 cell[2].
Withangulatin A (0-10 µM, 12 h) binds to peroxiredoxin 6 (PRDX6), inhibits the activities of glutathione peroxidase (GPx) and phospholipase A2 (iPLA2), promotes the generation of ROS[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:mouse T lymphocyte
-
Concentration:1.4-5.6 µM
-
Incubation Time:48 h
-
Result:Inhibited the proliferation.
-
Cell Line:mouse T lymphocyte
-
Concentration:1.4-5.6 µM
-
Incubation Time:48 h
-
Result:Reduced the expression of COX-2.
-
Cell Line:LX-2
-
Concentration:0-20 µM
-
Incubation Time:24 h
-
Result:Induced apoptosis.
Withangulatin A (5-10 mg/kg, ip, 3 times a week for 4 weeks) exhibits antitumor effect in mouse H1975 xenograft models[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Xylene-induced mouse ear swelling models[1]
-
Dosage:5-20 mg/kg
-
Administration:ip, once daily for 5 days
-
Result:Inhibited xylene-induced mouse ear swelling.
Reduced the levels of IL-2 and IL-6 in mouse serum.
-
Animal Model:Mouse H1975 xenograft models[3]
-
Dosage:5-10 mg/kg
-
Administration:ip, 3 times a week for 4 weeks
-
Result:Inhibited tumor growth.
Chemical Information
-
CAS No. 120824-03-5
-
Appearance Solid
-
Molecular Weight 526.62
-
Formula C30H38O8
-
Color White to off-white
-
SMILES
C[C@]12[C@@]3([C@H](C=CC2=O)O)[C@](C[C@]4([H])[C@]1([H])CC[C@]5([C@]4([C@H](C=C5[C@@H]([C@@]6([H])CC(C)=C(C(O6)=O)C)C)OC(C)=O)O)C)([H])O3
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
PRDX6 Prevents NNMT Ubiquitination and Degradation as a Nonenzymatic Mechanism to Promote Ovarian Cancer Progression. [Abstract]2025 Jan 30:e2416484. PMID: 39887931
Solvent & Solubility
DMSO : 3 mg/mL (5.70 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (289 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lijuan Sun, et al. Anti-inflammatory function of Withangulatin A by targeted inhibiting COX-2 expression via MAPK and NF-kappaB pathways. J Cell Biochem. 2010 Feb 15;109(3):532-41. [Content Brief]
[2]. Liu Q, et al., Withagulatin A inhibits hepatic stellate cell viability and procollagen I production through Akt and Smad signaling pathways. Acta Pharmacol Sin. 2010 Aug;31(8):944-52. [Content Brief]
[3]. Chen C, et al., Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer. Redox Biol. 2021 Oct;46:102130. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8989 mL | 9.4945 mL | 18.9890 mL | 47.4726 mL |
| 5 mM | 0.3798 mL | 1.8989 mL | 3.7978 mL | 9.4945 mL |
Powered by Bioz